Concepedia

Christian Brandl

CB

Statistics

Publications

15

Citations

3.1K

H-Index

14

Active since

2002

Affiliations

Amgen (Germany)(Current)

3D-Micromac (Germany)

Amgen (United States)

Charité - Universitätsmedizin Berlin

Universitätsklinikum Würzburg

Christian Brandl is an author at Amgen (Germany) specializing in life sciences, immunology, and cancer immunotherapy.

ORCID

Publications per year

2002–2023

15

Publications

15

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

Ralf C. Bargou, Eugen Leo, Gerhard Zugmaier et al. · Science · 2008 · 1.1K citations

, , +17

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Matthias Klinger, Christian Brandl, Gerhard Zugmaier et al. · Blood · 2012 · 463 citations

, , +17

Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody

Torsten Dreier, Grit Lorenczewski, Christian Brandl et al. · International Journal of Cancer · 2002 · 354 citations · Full text

, , +17

Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody construct

Patrick Hoffmann, Robert Hofmeister, Klaus Brischwein et al. · International Journal of Cancer · 2005 · 344 citations · Full text

, , +16

Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications

Min Zhu, Benjamin Wu, Christian Brandl et al. · Clinical Pharmacokinetics · 2016 · 211 citations

, , +16

1–5 of 15